Buy FOXO4-DRI 10mg

FOXO4-DRI is a D-retro-inverso (DRI) peptide — a form in which all amino acids are replaced by their D-stereoisomers and the sequence is reversed — that mimics a critical domain of the FOXO4 transcription factor. This structural modification confers complete resistance to proteolytic degradation while preserving the ability to bind target proteins, granting FOXO4-DRI an exceptionally long half-life in biological fluids compared to native L-peptides. The peptide's functional target is the interaction between FOXO4 and p53, two proteins that form an aberrant survival complex specifically in senescent cells, allowing those cells to evade the apoptosis that would normally clear them from tissues. In normally stressed young cells, p53 activation drives a transcriptional program that leads to either cell cycle arrest (if damage is reversible) or apoptosis (if damage is irreparable). In senescent cells, however, FOXO4 is upregulated and sequesters p53 in the nucleus in a complex that blocks p53's pro-apoptotic activity while preserving its ability to enforce cell cycle arrest. The result is a cell that is permanently growth-arrested, metabolically active, and secreting a damaging cocktail of inflammatory cytokines, proteases, and growth factors — the senescence-associated secretory phenotype (SASP) — but that cannot be cleared by its own apoptotic machinery. FOXO4-DRI disrupts this complex by competitively occupying the FOXO4 binding interface on p53, freeing p53 to engage its canonical apoptotic targets and trigger selective elimination of the senescent cell. The selectivity of FOXO4-DRI for senescent over normal cells is its most pharmacologically remarkable property. Proliferating cells do not express the elevated FOXO4 levels characteristic of senescence, so the p53-FOXO4 complex FOXO4-DRI disrupts is essentially absent. In the original van Deursen laboratory experiments, treatment of normal fibroblasts with FOXO4-DRI at doses effective against senescent cells produced no measurable cytotoxicity, confirming target-dependent rather than nonspecific cell killing. This contrasts favorably with other senolytic approaches such as navitoclax (ABT-263), which inhibits BCL-2 family proteins broadly and causes significant thrombocytopenia by killing platelets — a major limitation for clinical translation. The downstream consequences of senescent cell clearance extend well beyond local tissue effects. Senescent cells accumulate with age in virtually all organ systems — adipose tissue, liver, kidney, vascular endothelium, skeletal muscle, and brain — and their SASP drives systemic chronic inflammation, termed "inflammaging." Transplantation of as few as 500,000 senescent cells into young healthy mice has been shown to cause measurable multi-organ dysfunction and premature death. Conversely, genetic or pharmacological clearance of senescent cells in naturally aged mice produces striking improvements in physical function, cognition, kidney function, cardiac output, and even median lifespan. FOXO4-DRI offers a molecularly precise route to achieve this clearance.

FOXO4-DRI is a relatively long peptide (18 amino acids) composed entirely of D-amino acids in reverse sequence — a synthesis complexity that results in significantly higher production costs and greater quality variability than simpler peptides. The defining quality metric is chiral purity: each residue must be confirmed as the D-stereoisomer, since even a single L-amino acid substitution changes the peptide's proteolytic resistance and potentially its binding specificity. Reputable suppliers will provide mass spectrometry data confirming the molecular weight and HPLC chromatograms with purity ≥95%; accept nothing less than 95% purity for research-grade material. The original Baar et al. study used FOXO4-DRI at 1.5 mg/kg intraperitoneally in mice, typically three times per week for 10 days. Human dose translation using standard allometric scaling from mouse to human (body surface area normalization, factor of ~12) suggests equivalent human doses in the range of 1–5 mg total per injection depending on body weight — substantially lower than the raw milligram-per-kilogram figure suggests because human body surface area to body weight ratio is lower than in mice. Self-reported protocols in the biohacking community have used 1–2 mg subcutaneously per session over similar 10-day cycles, though no systematic human dose-finding studies exist. Storage requires −20 °C for the lyophilized powder, protected from light and moisture. Reconstitute in sterile bacteriostatic water and use within 2–4 weeks when refrigerated. Because FOXO4-DRI is a research compound with no approved human clinical indication, sourcing from suppliers who provide lot-specific third-party testing documentation is essential. Batch-to-batch consistency for D-peptides is a known manufacturing challenge, making established suppliers with quality track records far preferable over anonymous sources.

The senolytic landscape includes several competing approaches: dasatinib (a BCL tyrosine kinase inhibitor) combined with quercetin (a natural flavonoid), navitoclax (BCL-2/BCL-XL inhibitor), and FOXO4-DRI. Dasatinib+quercetin is the most clinically studied combination, with multiple Phase I/II trials in conditions including IPF, diabetic kidney disease, and Alzheimer's disease. Its safety profile is largely characterized, though dasatinib has known cardiovascular and hepatotoxic risks. Navitoclax is potently senolytic but causes dose-limiting platelet destruction due to BCL-XL dependence of platelets — a serious limitation that has restricted its clinical development outside of oncology. FOXO4-DRI's advantage is mechanistic precision. By targeting the FOXO4-p53 interaction that is specifically upregulated in senescent cells, FOXO4-DRI avoids the broad anti-apoptotic signaling disruption caused by BCL-2 family inhibitors. The D-retro-inverso design also confers extreme protease resistance, giving FOXO4-DRI a substantially longer functional half-life than equivalent L-peptides. The primary disadvantage relative to D+Q is the absence of human clinical trial data — all FOXO4-DRI evidence is preclinical. For researchers seeking the best-characterized senolytic with human evidence, D+Q remains the reference standard; for those prioritizing mechanistic selectivity and willing to work with early-stage compounds, FOXO4-DRI represents the most targeted approach currently available.